Multiple sclerosis is an often-debilitating disease of the central nervous system. Studies have shown cannabis is effective in managing symptoms associated with the disease and may also be beneficial for limiting the disease’s progression.
Overview of Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the central nervous system that often leads to disablement. The body’s immune system mistakenly attacks and destroys the myelin sheath that protects and insulates the nerve fibers. Myelin increases the speed at which electrical impulses move between the brain and the rest of the body and are essential for the nervous system to function properly. A loss of myelin causes signals between the brain and the body to become disrupted.
Common symptoms associated with multiple sclerosis include fatigue, walking difficulties, numbness, muscle spasms, weakness, vision problems, dizziness, bladder and bowel problems, pain, depression, and emotional and cognitive changes. In rare cases, seizures can occur.
The most common type of multiple sclerosis is relapsing-remitting MS (RRMS), which is characterized by day or weeklong relapses that can feature new symptoms, followed by periods of quiet remission that can last for months or years. Patients with RRMS will commonly transition into secondary-progressive MS (SPMS), in which the disease progresses more steadily, with or without relapses. Other types include primary-progressive MS (PPMS), which is characterized by neurological function progressively worsening over time, and progressive-relapsing MS (PRMS), which features a steady progression but has occasional exacerbations along the way.
The cause of multiple sclerosis is unknown, but the disease mostly affects women and those between the age of 15 and 60.
There is no cure for multiple sclerosis. Treatment efforts, including the administering of corticosteroids to reduce nerve inflammation and plasma exchange, can help to manage symptoms and potentially limit the disease’s progression.
Findings: Effects of Cannabinoids and CBD on Multiple Sclerosis
Research findings suggest that cannabis could slow the neurodegenerative process of multiple sclerosis. Studies have shown that cannabinoids are involved in the regulation of the immune system by way of acting upon the cannabinoid receptors of the endocannabinoid system. Cannabinoids have shown they can modulate the inflammatory reaction and assist in neuroregeneration2,6. In one study, cannabinoids demonstrated neuroprotective effects during an animal model of multiple sclerosis, reducing the damage to myelin caused from inflammation10. Another study found that cannabinoids administered to animals with a model of multiple sclerosis reduced neurological disability, improved motor coordination and limited the progression of the disease3.
Cannabis can help multiple sclerosis patients manage the symptoms associated with their disease. Cannabis has shown to be effective at reducing pain, muscle stiffness and spasms in multiple sclerosis patients5,12. In one study, multiple sclerosis patients saw significant improvements in muscle spasticity and reduced sleep disturbances after four weeks of cannabis treatment8. A similar study found that multiple sclerosis patients experienced pain and sleep improvements after five weeks of treatment with cannabis containing both tetrahydrocannabinol (THC) and cannabidiol (CBD)11. In a questionnaire survey, multiple sclerosis patients responded that cannabis was effective in improving spasticity, chronic pain of extremities, tremors, emotional dysfunctions, fatigue, double vision, bowel and bladder dysfunctions, dysfunctions of walking and balance and memory loss1.
There is some evidence that suggests that cannabis may worsen cognitive problems in multiple sclerosis patients. Multiple sclerosis patients that were regular users of street cannabis have scored significantly worse on cognitive function tests4,9.
States That Have Approved Medical Cannabis for Multiple Sclerosis
Currently, 15 states have approved medical cannabis specifically for the treatment of multiple sclerosis. These states include Alaska, Connecticut, Florida, Georgia, Illinois, Louisiana, Maine, Massachusetts, New Hampshire, New Jersey, New Mexico, New York, Ohio, Pennsylvania and Vermont. In Washington D.C., any condition can be approved for medical cannabis as long as a DC-licensed physician recommends the treatment.
A number of other states will consider allowing medical cannabis to be used for the treatment of multiple sclerosis with the recommendation from a physician. These states include: California (any debilitating illness where the medical use of cannabis has been recommended by a physician), Nevada (other conditions subject to approval), Oregon (other conditions subject to approval), Rhode Island (other conditions subject to approval), and Washington (any “terminal or debilitating condition”).
Several states have approved medical cannabis specifically to treat “chronic pain,” which is a symptom commonly associated with multiple sclerosis. These states include: Alaska, Arizona, California, Colorado, Delaware, Hawaii, Maine, Maryland, Michigan, Montana, New Mexico, Ohio, Oregon, Pennsylvania, Rhode Island and Vermont. The states of Nevada, New Hampshire, Ohio and Vermont allow medical cannabis to treat “severe pain.” The states of Minnesota, Ohio, Pennsylvania and Washington have approved cannabis for the treatment of “intractable pain.”
Several states will allow medical cannabis for the treatment of spasms, which can arise in those with multiple sclerosis. These states include: California, Colorado, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Minnesota, Montana, Nevada, Oregon, Rhode Island and Washington.
Patients whose multiple sclerosis causes seizures can use medical cannabis to treat that specific symptom in several states, including Alaska, Arizona, California, Colorado, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Minnesota, Montana, Nevada, New Hampshire, Ohio, Oregon, Pennsylvania (intractable seizures), Rhode Island, Tennessee (intractable seizures), Vermont and Washington.
Recent Studies on Cannabinoids and CBD’s Effect on Multiple Sclerosis
Cannabinoids were effective at reducing neurological disability and the progression of the disease in mice with an animal form of MS.
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
Four weeks of cannabis treatment caused significant spasm improvements in MS patients.
A randomized double-blind-placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
Five weeks of cannabis treatment significantly reduced pain and improved sleep in MS patients.
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
- Consroe, P., Musty, R., Rein, J., Tillery, W., and Pertwee, R. (1997). The perceived effects of smoked cannabis on patients with multiple sclerosis. European Neurology, 38(1), 44-48.
- Croxford, J.L., Pryce, G., Jackson, S.J., Ledent, C., Giovannoni, G., Pertwee, R.G., Yamamura, T., and Baker, D. (2008, January). Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. Journal of Neuroimmunology, 193(1-2), 120-9.
- de Lago, E., Moreno-Martet, M., Cabranes, A., Ramos, J.A., Fernandez-Ruiz, J. (2012, June). Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology, 62(7), 2299-308.
- Honarmand, K., Tierney, M.C., O’Connor, P., Feinstein, A., (2011, March 29). Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology, 76(13), 1153-60.
- Koppel, B.S., Brust, J.C. M., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., and Gloss, D. (2014). Systematic review: Efficacy and safety of medical Cannabis in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 82(17), 1556–1563.
- Kubajewska, I., and Constantinescu, C.S. (2010, August). Cannabinoids and experimental models of multiple sclerosis. Immunobiology, 215(8), 647-57.
- Multiple sclerosis. (2015, October 1). Mayo Clinic. Retrieved from http://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/home/ovc-20131882.
- Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., Davies, P. (2011, September). A randomized double-blind-placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology, 18(9), 1122-31.
- Pavisian, B., MacIntosh, B.J., Szilagyi, G., Staines, R.W., O’Connor, P., Feinstein, A. (2014, May 27). Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology, 82(21), 1879-87.
- Pryce, G., Ahmed, Z., Hankey, D.J., Jackson, S.J., Croxford, J.L. Pocock, J.M., Ledent, C., Petzold, A., Thompson, A.J., Giovannoni, G., Cuzner, M.L., and Baker, D. (2003, October). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 126(Pt 10), 2191-202.
- Rog, D.J., Nurmikko, T.J., Friede, T., and Young, C.A. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65(6), 812-19.
- Wade, D.T., Makela, P., Robson, P., House, H., and Bateman, C. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis, 10, 434-441.
- What Is MS? (n.d.). National Multiple Sclerosis Society. Retrieved from http://www.nationalmssociety.org/What-is-MS.